financetom
Business
financetom
/
Business
/
Seagate Technology Swings to Fiscal Q4 Earnings, Revenue Rises; Q1 Outlook Set -- Shares Up After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Seagate Technology Swings to Fiscal Q4 Earnings, Revenue Rises; Q1 Outlook Set -- Shares Up After Hours
Jul 23, 2024 2:09 PM

04:57 PM EDT, 07/23/2024 (MT Newswires) -- Seagate Technology ( STX ) reported fiscal Q4 non-GAAP earnings late Tuesday of $1.05 per diluted share, compared with a loss of $0.18 per share a year earlier.

Analysts polled by Capital IQ expected $0.75 per share.

Revenue for the quarter ended June 28 was $1.89 billion up from $1.60 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.87 billion.

For fiscal Q1, the company expects a non-GAAP EPS of $1.40 per diluted share, plus or minus $0.20. Analysts polled by Capital IQ expect $1.17 per share.

Fiscal Q1 revenue is projected at $2.10 billion, plus or minus $150 million. Analysts surveyed by Capital IQ expect $2.07 billion.

Seagate ( STX ) said it kept its quarterly cash dividend at $0.70 per share, payable Oct. 7 to shareholders of record on Sept. 23.

Shares of Seagate Technology ( STX ) were up nearly 7% in after-hours activity.

Price: 112.50, Change: +7.20, Percent Change: +6.84

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Shuttle Pharmaceuticals (SHPH) Is Extremely Volatile Today
Why Shuttle Pharmaceuticals (SHPH) Is Extremely Volatile Today
Sep 5, 2024
Shuttle Pharmaceuticals Holdings Inc ( SHPH ) shares are trading lower by 1.69% to $2.33 Thursday morning, reversing following earlier strength, after the company announced the issuance of U.S. Patent No. 12,077,515, titled “Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease.” The stock traded higher by as much as 44% to $3.41 during Thursday’s pre-market session. The patent...
Argentina Lithium Exercises Options to Acquire Lithium-Prospective Properties
Argentina Lithium Exercises Options to Acquire Lithium-Prospective Properties
Sep 5, 2024
10:31 AM EDT, 09/05/2024 (MT Newswires) -- Argentina Lithium & Energy ( LILIF ) was at last look unchanged and trading near 52 week lows after saying Thursday that it has fully exercised its options to acquire 22 lithium-prospective properties totaling 25,391 hectares at its Rincon West, Pocitos and Antofalla North projects. The properties are subject to production royalties and...
C3.ai Delivers Good Fiscal Q1 With 'Some Spots of Weakness,' Wedbush Says
C3.ai Delivers Good Fiscal Q1 With 'Some Spots of Weakness,' Wedbush Says
Sep 5, 2024
11:22 AM EDT, 09/05/2024 (MT Newswires) -- C3.ai ( AI ) delivered good fiscal Q1 results and reaffirmed its fiscal 2025 revenue guidance, though there were some spots of weakness, Wedbush Securities said Thursday. Late Wednesday, the company reported fiscal Q1 financial results that surpassed Wall Street's estimates. C3.ai ( AI ) reaffirmed its fiscal 2025 revenue guidance of $370...
Eli Lilly partners with AI-focused Genetic Leap to develop RNA-based drugs
Eli Lilly partners with AI-focused Genetic Leap to develop RNA-based drugs
Sep 5, 2024
(Adds background throughout) Sept 5 (Reuters) - U.S. drugmaker Eli Lilly ( LLY ) has signed a research deal with privately held AI-focused firm Genetic Leap to develop genetic medicines, the latter said on Thursday. WHY IT'S IMPORTANT Major drugmakers have been experimenting with artificial intelligence to discover new drugs, find patients for clinical trials and reduce the number of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved